Deakin University
Browse
bogatyreva-differential-2011.pdf (499.69 kB)

Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.

Download (499.69 kB)
journal contribution
posted on 2011-08-01, 00:00 authored by C Cullinane, D Dorow, S Jackson, B Solomon, Kat Bogatyreva, D Binns, R Young, M Arango, J Christensen, G McArthur, R Hicks
The ability of PET to image functional changes in tumors is increasingly being used to evaluate response and predict clinical benefit to conventional and novel cancer therapies. Although the use of (18)F-FDG PET is well established, 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET has potential advantages as a more specific marker of cellular proliferation. c-MET signaling is frequently dysregulated in cancer and is therefore an attractive therapeutic target. Crizotinib (PF-2341066) is a novel adenosine triphosphate-competitive c-MET kinase inhibitor with antitumor activity in a range of tumor models. The aim of this study was to investigate the utility of PET of glucose metabolism and cell proliferation to monitor tumor response to crizotinib in 2 cell lines with aberrant c-MET signaling.

History

Journal

Journal of nuclear medicine

Volume

52

Issue

8

Pagination

1261 - 1267

Publisher

Society of Nuclear Medicine

Location

Chicago, Il.

ISSN

1535-5667

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

2011, Society of Nuclear Medicine

Usage metrics

    Research Publications

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC